Inhibition of either vascular endothelial growth factor receptor or mammalian target of rapamycin (mTOR) signaling improves outcomes in patients with several advanced solid tumors. We conducted a phase I trial of temsirolimus with pazopanib to investigate the feasibility of simultaneous 'vertical inhibition' of vascular endothelial growth factor receptor and mTOR pathways. Patients with advanced solid tumors, no previous pazopanib or mTOR inhibitor, good performance status, and acceptable end-organ function were eligible. In a typical 3 + 3 escalation design starting at temsirolimus 15 mg by an intravenous infusion weekly and pazopanib 400 mg orally daily, we defined dose-limiting toxicity (DLT) as attributable grade 3 or higher nonhematologic adverse events in the first 28-day cycle and the maximum tolerable dose as the maximum dose level at which less than two patients experienced DLT. At the initial dose level, two patients had four DLTs (anorexia, fatigue, hyponatremia, and hypophosphatemia). After reduction to temsirolimus 10 mg intravenous infusion weekly and pazopanib 200 mg orally daily, one of three patients had DLT (fatigue) and the first patient in the subsequent expansion had dose-limiting hypophosphatemia. Attributable grade 3 or higher adverse events in more than one patient included leukopenia, neutropenia, fatigue, and hypophosphatemia. Tumor reduction not fulfilling the RECIST criteria for partial response was the best response in four of seven evaluable patients. The combination of temsirolimus and pazopanib was not feasible at clinically meaningful doses in this population because of constitutional and electrolyte disturbances.
Introduction
The results of randomized phase III clinical trials led to the recent regulatory approval of several inhibitors of the vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) pathways in different tumor types. However, numerous overlapping signaling pathways are involved in tumor proliferation and growth, thereby limiting the efficacy of single-target inhibition. A strategy of multitarget 'vertical inhibition' of the overlapping VEGF and mTOR pathways by combination therapy may overcome drug resistance and translate to enhanced efficacy over each single agent alone in renal cell cancer (RCC), pancreatic neuroendocrine tumors, and other malignancies [1, 2] . Indeed, combined VEGF and mTOR pathway inhibition has shown promise in preclinical solid tumor models [3] [4] [5] .
Temsirolimus (CCI-779) is an intravenous inhibitor of mTOR that is approved by the US Food and Drug Administration for the treatment of advanced RCC on the basis of the results of a large phase III trial of 626 patients with previously untreated, poor-prognosis metastatic RCC [6] . Patients were randomized to temsirolimus alone, interferon-a alone, or the combination of temsirolimus and interferon-a. The patients who received temsirolimus alone had prolonged overall (hazard ratio, 0.73; P = 0.008) and progression-free survival (P < 0.001) compared with those who received interferon-a alone. There was no additional benefit to the combination arm. Temsirolimus monotherapy was well tolerated, with fewer serious adverse events compared with interferon-a (P = 0.02). These results show that temsirolimus is active and well tolerated in advanced RCC and provide the basis for exploration of temsirolimus-based combinations.
Pazopanib is an orally bioavailable tyrosine kinase inhibitor that selectively inhibits VEGF receptor (VEGFR)-1, -2, and -3, as well as c-kit and plateletderived growth factor receptor [7] . Pazopanib achieved regulatory approval for advanced RCC on the basis of the results of an international placebo-controlled phase III trial of 435 treatment-naive or cytokine-pretreated patients [8] . Progression-free survival was prolonged from 4.2 to 9.2 months in the pazopanib-treated group (hazard ratio, 0.46; P < 0.001). The toxicity profile was acceptable; grade 3 or higher events included diarrhea, hypertension, asthenia, and transaminitis. Importantly, pazopanib's toxicity profile appeared to compare favorably with other VEGFR tyrosine kinase inhibitors, making pazopanib an attractive agent to combine with other biologic agents as part of combination therapy.
We designed this phase I trial to explore the possibility of combined mTOR and VEGFR pathway inhibition using temsirolimus and pazopanib, to define the toxicities of the combination, and to establish a maximum tolerated dose of each agent when used in combination for use in further studies.
Methods

Patients
Eligible patients were aged 18 years and older with refractory solid tumors and a Zubrod Performance Status of 0-2. Any number of previous treatments was allowed as long as treatment was completed at least 2 weeks before registration and all toxicities had resolved to grade 1 or less. Further inclusion criteria included the ability to provide informed consent, the ability to take oral medication, and acceptable end-organ function defined by an absolute neutrophil count Z 1500/mm 3 , platelet count Z 100 000/mm 3 , total bilirubin within institutional normal limits, alanine aminotransferase and aspartate aminotransferase r 2.5 times the upper limit of normal (ULN) or r 5 times ULN for patients with liver involvement, and creatinine r 1.5 times ULN.
Exclusion criteria included any previous treatment with temsirolimus, everolimus, rapamycin, or pazopanib and the need for ongoing treatment with warfarin or low-molecularweight heparin. Patients were excluded for significant cardiac comorbidities including New York Heart Association class II or greater congestive heart failure, myocardial infarction within the past 6 months, new onset of angina within the previous 3 months, corrected QT interval >480 ms, and systolic blood pressure >160 mmHg or diastolic blood pressure >90 mmHg despite optimal medical management. Further exclusion criteria included thrombotic or embolic events within the past 6 months, evidence of bleeding diathesis or coagulopathy, fasting cholesterol >350 mg/dl, and fasting triglycerides >400 mg/dl. Patients with major surgery, open biopsy, or significant traumatic injury within the previous 4 weeks were also excluded, as were patients with nonhealing wound, ulcer, or bone fracture or clinically serious active infection. The study protocol was reviewed and approved by the institutional review board of the University of California, Davis. All patients provided written informed consent before treatment.
Study procedures
Before registration, patients underwent an assessment of history and physical examination that included height, weight, performance status, vital signs, and a pregnancy test for all women of child-bearing potential. Although measurable disease was not mandated, radiographic tumor assessment was required within 4 weeks of registration. Tumor measurements were subsequently performed every 8 weeks and responses were evaluated using the RECIST criteria, version 1.0 [9] . Assessment of history and physical examination were performed by the treating physician weekly during the first 4-week cycle and then once every 4 weeks. An electrocardiogram was performed for assessment of the corrected QT interval each cycle. A blood pressure diary was reviewed at each study visit and toxicity was monitored through the trial using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0).
Treatment plan
We enrolled patients in a standard 3 + 3 design. The initial doses were 15 mg of temsirolimus by an intravenous infusion over 30 min weekly and 400 mg of pazopanib orally daily. Patients were premedicated with diphenhydramine 25-50 mg intravenous infusion or equivalent B30 min before temsirolimus infusion. No intrapatient dose escalation was allowed. Dose modification of both temsirolimus and pazopanib for grade 3 or higher toxicity was allowed according to a defined schedule.
Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or greater nonhematologic toxicity (excluding serum triglycerides up to 1500 mg/dl that recovered to grade 1 or less within 1 week), grade 4 or greater thrombocytopenia, grade 4 or greater febrile neutropenia requiring hospitalization, or treatment delay of more than 2 weeks as a result of unresolved toxicity during the first cycle of therapy. To be evaluable for DLT assessment, a patient must have received at least 1 complete cycle of treatment and be observed for at least 1 week after the fourth dose of temsirolimus or have experienced DLT in the first cycle. All patients enrolled were fully followed for toxicity, but patients who were not evaluable for DLT were replaced.
A preplanned lower dose level (-2) of temsirolimus 10 mg intravenous infusion weekly and pazopanib 200 mg orally daily was available if two or more patients experienced DLT at the initial level. If DLT attributable to the study drugs was experienced in exactly one of three patients, three more patients (for a total of 6) were treated at that dose level. Escalation was planned in successive cohorts of three to six patients and would terminate as soon as two or more patients experienced any DLT attributable to the study drugs at a given dose level other than the initial dose level or when six patients evaluable for DLT assessment were treated at full doses of both temsirolimus and pazopanib.
Treatment was continued in 4-week cycles until unaccep- deterioration, the patient withdrew consent, treatment was delayed for more than 2 weeks because of drug-related toxicity, or more than 4 weeks because of any other reason.
Statistical analysis
Data analysis included descriptive summaries of baseline and demographic information. Toxicities were summarized by frequency and the maximum grade over the course of all cycles of treatment. For patients with measurable disease and at least one follow-up assessment, tumor response was analyzed using the RECIST criteria.
Results
Patient characteristics
Dose escalation could not proceed beyond the first dose level because of DLTs. Thus, a total of only eight patients were finally enrolled. Baseline characteristics are summarized in Table 1 . The majority of patients had excellent performance status and had received moderate pretreatment (median 2 prior regimens). One patient was treatment naive, three patients had received previous treatment with a VEGFR tyrosine kinase inhibitor (sunitinib, sorafenib, or ABT-869), and five patients had received one to three previous cytotoxic chemotherapy regimens. The most common tumor site was RCC (38%), although patients with five separate tumor types were represented.
Treatment and adverse events
We enrolled four patients at the initial dose level. One patient was ineligible for DLT assessment because of an unscheduled break in therapy during cycle 1 that was unrelated to treatment. This patient was included in the summaries of overall toxicity and treatment response. Among eligible patients at the initial dose level, two patients experienced DLTs in the first cycle of treatment including anorexia, fatigue, hyponatremia, and hypophosphatemia. We subsequently enrolled three patients to dose level -2 and observed a DLT (fatigue) in one of these three. After the first patient in the expansion of dose level -2 developed grade 3 hypophosphatemia, we aborted further enrollment onto the study for lack of feasibility at the lowest dose tested. DLT at each dose level is summarized in Table 2 .
A total of 22 complete cycles of the combination were administered. A majority of patients experienced at least one episode of grade 3 or higher toxicity (88%). Common nonhematologic toxicities included fatigue, anorexia, diarrhea, mucositis, nausea, vomiting, and electrolyte and cholesterol abnormalities ( Table 3 ). The most common grade 3 or higher toxicities included leukopenia, neutropenia, fatigue, and hypophosphatemia. Electrolyte disturbances were most often asymptomatic and transient, although one patient developed mild generalized muscular weakness associated with grade 3 hypophosphatemia that resolved with phosphorus replacement and discontinuation of trial therapy.
Response
Seven patients had at least one follow-up imaging study performed to assess for response. The best overall response was stable disease in four patients (57%). Tumor shrinkage not fulfilling the criteria for RECIST partial response was observed in each of these four patients with stable disease.
Discussion
We observed unacceptably high rates of grade 3 and higher toxicities when temsirolimus and pazopanib were combined at doses far less than the approved dose of each agent as monotherapy. The lowest dose level tested (temsirolimus 10 mg intravenous infusion weekly and pazopanib 200 mg daily) was 40 and 25% of the clinical dose of each agent, respectively. The primary reason for intolerance of this combination was grade 3 and higher constitutional symptoms and electrolyte disturbances.
Our results are consistent with several other trials attempting to simultaneously combine VEGFR tyrosine kinase inhibitors with mTOR inhibitors. The concept of vertical VEGFR and mTOR inhibition was piloted in a phase I trial of the VEGFR tyrosine kinase inhibitor sunitinib and temsirolimus [10] . In that trial, two of three patients in the first cohort treated with temsirolimus 15 mg intravenous infusion weekly and sunitinib 25 mg orally once daily for 4 weeks, followed by a 2-week rest period experienced DLTs, primarily of the skin and soft tissue. As considerable toxicity was observed at low starting doses of both agents, the trial was closed for nonfeasibility. Phase I studies of the combination of sorafenib and temsirolimus in several different tumor types have been published or presented at major meetings [11] [12] [13] [14] . Although considered feasible in some of these trials, significant mucocutaneous toxicity, constitutional symptoms, and electrolytes disturbances were observed at moderate doses of each agent. Despite its modest toxicity profile as monotherapy, we found that pazopanib is not a better partner for combination with temsirolimus than sunitinib or sorafenib.
In addition, several trials of the oral mTOR inhibitor everolimus in combination with the VEGFR inhibitors sorafenib and sunitinib have been reported recently [15] [16] [17] [18] . In one study, the combination of fulldose sorafenib was tolerable with half-doses of everolimus, although DLT was observed in 25% of patients treated at these doses and full-dose everolimus with halfdose sorafenib was not tolerated [16] . Because of chronic toxicities observed at lower doses over time, no attempt was made to dose both drugs at the full monotherapy doses in this trial. In contrast, Amato et al. [15] found that full doses of everolimus and sorafenib could be administered without DLT, at least in their population of predominantly Zubrod 0 performance status patients with RCC. Significant modifications of both the dose and the schedule of everolimus and sunitinib were required to find a tolerable dose of this combination, and the dose had to be reduced further if patients were to be treated chronically [17] .
In this trial, we intended to collect pharmacokinetic data only in an expanded cohort at the anticipated maximum tolerated dose at the top of the dose-escalation schema. Thus, no pharmacokinetic data were collected for the patients treated at the initial dose levels and we cannot determine whether an unfavorable pharmacokinetic interaction occurred between these two agents. However, no pharmacokinetic interactions between mTOR inhibitors and VEGFR tyrosine kinase inhibitors have been observed in the studies in which pharmacokinetic analyses were carried out [11] [12] [13] 16, 17] . Interestingly, commonly observed grade 3 or higher toxicities include constitutional, mucocutaneous, and electrolyte disturbances and are similar across these trials. This suggests that overlapping mTOR inhibitor and VEGFR tyrosine kinase inhibitor toxicities accounts for the inability to combine these classes of agents in most settings.
We included patients with refractory advanced solid tumors with any number of previous therapies, which may have affected tolerance to the study treatment. Indeed, three patients had received treatment with a previous VEGFR tyrosine kinase inhibitor, which had generally been well tolerated. Nonetheless, DLT was observed in the first cycle of treatment even in a patient with treatment-naive advanced RCC at the lowest tested dose. Finally, this trial was designed to assess the concurrent administration of pazopanib and temsirolimus. Future studies could consider alternative strategies such as a single-agent run-in or altered schedules, especially given that the concurrent administration of VEGFR and mTOR inhibitors has not proven successful when administered concurrently.
In conclusion, the combination of temsirolimus and pazopanib is not feasible for patients with advanced solid tumors, primarily because of constitutional and electrolyte disturbances. Further research to understand the adverse interaction between VEGFR and mTOR inhibitors is required. Future studies should also evaluate alternative strategies to mitigate the toxicity observed with these combinations.
